| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 23 May 2025 | 12 May 2025 |
| Glenmark Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2025 inter alia to consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the quarter and year ended March 31 2025 and to consider and recommend dividend if any on Equity shares for the year ended March 31 2025. The Board of Directors of Glenmark Pharmaceuticals Limited at its meeting held on 23rd May, 2025, which commenced at 02.00 p.m. and concluded at 04:54 p.m., considered and approved the following: 1. Audited Financial Results for the quarter and year ended March 31, 2025. Pursuant to regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, find enclosed herewith the said results together with Auditors Report and Declaration of unmodified opinion. These are also being made available on the website of the Company at www.glenmarkpharma.com. 2. Recommended Dividend @ 250% i.e. Rs. 2.5/- per share (face value of Re. 1/- each) on the Equity Share Capital of the Company for the financial year 2024-25 subject to the approval of the Shareholders at the ensuing Annual General Meeting. (As Per BSE Announcement Dated on: 23/05/2025) | ||
| Board Meeting | 14 Feb 2025 | 3 Feb 2025 |
| GLENMARK PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2025 inter alia to consider and approve the Unaudited Financial Results of the Company for the Third Quarter and Nine Months ended December 31 2024. Outcome of the Board Meeting dated 14th February, 2025. (As Per Bse Announcement Dated on 14.02.2025) | ||
| Board Meeting | 14 Nov 2024 | 30 Oct 2024 |
| GLENMARK PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2024 inter alia to consider and approve the Unaudited Financial Results of the Company for the second quarter and half year ended September 30 2024. Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the Board at its meeting held today has approved the unaudited financial results for the Second Quarter and Half Year ended 30th September, 2024. The said Board Meeting commenced at 02:00 p.m. and ended at 6.20 p.m. (As Per BSE Announcement Dated on: 14/11/2024) | ||
| Board Meeting | 14 Aug 2024 | 31 Jul 2024 |
| GLENMARK PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2024 inter alia to consider and approve the Unaudited Financial Results of the Company for the First quarter ended June 30 2024. Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the Board at its meeting held today has approved the unaudited financial results for the First Quarter ended 30th June, 2024 (As per BSE Announcement Dated on 14/08/2024) | ||
| Board Meeting | 10 Jul 2024 | 10 Jul 2024 |
| Disclosure pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 is attached for your records. | ||
Here are some of the stocks that may see significant price movement today: Glenmark Pharma, Ashok Leyland, NTPC, etc.
ISB 2001 is a tri-specific antibody therapeutic for targeting BCMA and CD38 on myeloma cells, as well as CD3 on T cells.
The reshuffle comes after VS Mani, the company's current chief, announced early retirement; he will officially retire as chief on May 26, 2025 after an eight-year career with the company.
This approval would allow Glenmark Therapeutics Inc., USA to market the product in the US market and would further fortify its ophthalmic portfolio.
Acetylcysteine Injection will be launched in 6 gm/30 mL (200 mg/mL) single-dose vials, and will be made available to hospitals and other system-wide healthcare providers.
The lawsuits included one on a generic version of Zetia, a cholesterol drug, as well as four other lawsuits involving Vytorin, a combination drug that contains Zetia.
EBITDA surged to ₹600.3 crore, up from a loss of ₹208.7 crore in the year-ago quarter, indicating better operational efficiency
It also appropriates ₹5.86 crore that Glenmark had already paid for surrendering IGST refunds relating to non-realisation of export proceeds.
According to a statement from the firm, the Travoprost ophthalmic solution (0.004% ionic buffered solution) is both bioequivalent and therapeutically equivalent to the reference listed medication
The company also reported revenue from operations to ₹3433.7 Crore. The EBITDA margin for the quarter that ended on September 30, 2024 stands at 17.5%.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
